Subscribe
gguy / Shutterstock.com
15 August 2025NewsAmericasMarisa Woutersen

Judge overturns Amgen’s $50m damages loss

A pair of patents behind an infringement case that proved expensive for Amgen have been found “unenforceable due to inequitable conduct”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025   Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026.
Americas
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
2 July 2025   Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.
Americas
Regeneron hits Amgen over its blockbuster eye disease treatment
19 June 2025   The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.


Editor's picks

Latham steps into dispute over $6bn treatment, replacing Kirkland
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

Editor's picks

Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

More on this story

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025   Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026.
Americas
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
2 July 2025   Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.
Americas
Regeneron hits Amgen over its blockbuster eye disease treatment
19 June 2025   The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.

More on this story

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025   Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026.
Americas
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
2 July 2025   Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.
Americas
Regeneron hits Amgen over its blockbuster eye disease treatment
19 June 2025   The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.

More features

Weil adds two more litigators from larger rival
Why the PTAB’s new expedited filing dates for AIA petitions is positive
Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Latham steps into dispute over $6bn treatment, replacing Kirkland
Patent pollution: Emissions charter aims to clean up IP
Why Trump’s revenue-raising patent plan is riddled with problems
Harvard’s patent portfolio at risk as Trump turns up the pressure
Weil adds leaders from Latham to head up tech and life sciences